"""
Question: 1101 

Evidence: We thus analyzed baseline study enrollment data collected through a randomized controlled trial entitled “Project YES! Youth Engaging for Success” in order to determine the prevalence and characteristics of HIV drug resistance among ART- experienced youth, aged 15 to 24 years, attending four HIV care clinics in Ndola, Zambia. From December 2017 through May 2018, a total of 276 youth age 15 and 24 years from four clinics were recruited into the parent Project YES! study.

Rationale: The paper describes a new cross-sectional analysis of data collected specifically for this study (Project YES!) and provides the study timeframe and recruitment details, indicating the data were previously unpublished at the time of reporting.

Answer: Yes
"""

"""
Question: 1102 

Evidence: Participants with viral failure (VL >=1,000 copies/mL) underwent HIVDR testing which included analysis of mutations in the protease and reverse transcriptase genes. Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes. Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI).

Rationale: The methods explicitly state that HIV-1 sequences (PR and RT regions) were generated and assembled for analysis, indicating that the study reports HIV sequences derived from patient samples.

Answer: Yes
"""

"""
Question: 1103 

Evidence: A cross-sectional analysis of study enrollment data from the Project YES! Youth Engaging for Success randomized controlled trial was conducted. Participants with viral failure (VL >=1,000 copies/mL) underwent HIVDR testing which included analysis of mutations in the protease and reverse transcriptase genes.

Rationale: The study involved clinical samples from participants and genotypic resistance testing; there is no mention of laboratory in vitro passage experiments.

Answer: No
"""

"""
Question: 1104 

Evidence: Only viral load results with viral loads of ≥1000 copies/mL were further analyzed for HIVDR using the Stanford University HIV drug resistance mutations database. The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: The paper reports genotypic analyses interpreted via Stanford HIVdb and does not describe any phenotypic susceptibility testing (e.g., IC50/IC90) performed in vitro.

Answer: No
"""

"""
Question: 2101 

Evidence: Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI). The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: Although sequences were generated and analyzed, there is no mention of submitting sequences to GenBank or reporting GenBank accession numbers.

Answer: No
"""

"""
Question: 2102 

Evidence: Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI). The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: The paper does not provide any GenBank accession numbers for clinical isolates; therefore, it also does not provide such numbers for non-laboratory isolates.

Answer: No
"""

"""
Question: 2103 

Evidence: Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI). The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: No GenBank accession numbers are reported anywhere in the manuscript, so specific accession numbers cannot be provided.

Answer: NA
"""

"""
Question: 2202 

Evidence: Drug mutations were categorized based on the WHO2017 drug mutation list and the Stanford HIV drug resistance database (Table 3). Overall, the 10 most common mutations were M184V (81%), K103N (65.5%), Y188C (36.2%), Y181C (36.2%), V106A (36.2), K65R (34.5%), K70RTQNE (32.8%), G190ASV (31.0%), K101EHP (31.0%) and E138AGQ (29.3%).

Rationale: The paper presents aggregate frequencies of mutations, not per-sample lists of mutations for individual isolates.

Answer: No
"""

"""
Question: 2301 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). 

Rationale: The methods explicitly state the species as HIV-1.

Answer: HIV-1
"""

"""
Question: 2302 

Evidence: Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes. The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: The paper does not mention viral subtypes; it focuses on gene regions and resistance interpretation without subtype reporting.

Answer: NA
"""

"""
Question: 2303 

Evidence: Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes. 

Rationale: This sentence specifies the sequenced gene regions.

Answer: Protease and reverse transcriptase (pol region, PR and RT)
"""

"""
Question: 2304 

Evidence: Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes. HIV Drug Resistance associated Mutations (DRM) were identified in 75.3% (58/77) of all successful sequences.

Rationale: PR and RT are components of the HIV pol gene; the study sequenced these regions and reported resulting resistance mutations.

Answer: Yes
"""

"""
Question: 2401 

Evidence: We thus analyzed baseline study enrollment data collected through a randomized controlled trial entitled “Project YES! Youth Engaging for Success” in order to determine the prevalence and characteristics of HIV drug resistance among ART- experienced youth, aged 15 to 24 years, attending four HIV care clinics in Ndola, Zambia. From December 2017 through May 2018, a total of 276 youth age 15 and 24 years from four clinics were recruited into the parent Project YES! study.

Rationale: The geographic location of sampling is explicitly stated as Ndola, Zambia.

Answer: Ndola, Zambia
"""

"""
Question: 2402 

Evidence: From December 2017 through May 2018, a total of 276 youth age 15 and 24 years from four clinics were recruited into the parent Project YES! study. 

Rationale: Recruitment dates indicate the time period when samples were obtained.

Answer: December 2017 to May 2018
"""

"""
Question: 2502 

Evidence: HIV drug resistance test using an Applied Biosystems Genetic Analyzer model 3500XL (Hitachi, Japan). Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI).

Rationale: Use of the ABI 3500XL capillary sequencer and manual sequence assembly indicates Sanger sequencing.

Answer: Yes
"""

"""
Question: 2503 

Evidence: HIV drug resistance test using an Applied Biosystems Genetic Analyzer model 3500XL (Hitachi, Japan). Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI).

Rationale: The described platform is a Sanger capillary sequencer and there is no mention of next-generation sequencing.

Answer: No
"""

"""
Question: 2504 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes.

Rationale: The methods describe direct population sequencing from plasma RNA without any cloning step.

Answer: No
"""

"""
Question: 2505 

Evidence: Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes. Sequences were assembled and manually edited using Sequencer version 4.5 software (Gene codes, Ann Arbor, MI).

Rationale: There is no mention of single-genome (single-template) amplification; the approach reflects standard population Sanger sequencing.

Answer: No
"""

"""
Question: 2506 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes.

Rationale: No molecular cloning procedures are described; sequencing was performed directly on extracted RNA-derived amplicons.

Answer: No
"""

"""
Question: 2601 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). Blood samples with a viral load of >1000 copies/mL (virologic treatment failure) were further subjected to an HIV drug resistance test.

Rationale: Sequencing was performed on plasma-derived viral RNA.

Answer: Yes
"""

"""
Question: 2602 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). 

Rationale: The methods specify plasma as the source; there is no mention of PBMC-derived sequencing.

Answer: No
"""

"""
Question: 2603 

Evidence: Out of these 99 participants, HIVDR amplification was successful in 77.8% (n = 77). HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany).

Rationale: The number of successful resistance genotypes (77) reflects the number of plasma virus sequences obtained.

Answer: 77
"""

"""
Question: 2604 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). There is no description of sequencing from PBMCs in the methods.

Rationale: Only plasma RNA sequencing was performed; PBMC sequencing was not described.

Answer: 0
"""

"""
Question: 2605 

Evidence: Participants with viral failure (VL >=1,000 copies/mL) underwent HIVDR testing which included analysis of mutations in the protease and reverse transcriptase genes. Blood samples with a viral load of >1000 copies/mL (virologic treatment failure) were further subjected to an HIV drug resistance test.

Rationale: Sequencing was performed on samples from individuals with active viremia (VL ≥1000), indicating active HIV replication.

Answer: Yes
"""

"""
Question: 2606 

Evidence: HIV-1 RNA was extracted from 140 milliliter of plasma using the Qiagene QiAmp viral RNA mini kit (QIAGEN, Germany). 

Rationale: Sequencing was performed on plasma viral RNA rather than proviral DNA, so it was not from the proviral DNA reservoir.

Answer: No
"""

"""
Question: 2701 

Evidence: Participants were 15 to 24 years old, who knew their HIV status, and had been on ART for at least 6 months. The mean age at the time of the study was 18.4 years.

Rationale: All participants were adolescents and young adults; no infants or young children were sampled at the time of sequencing.

Answer: No
"""

"""
Question: 2702 

Evidence: The cross-sectional analysis was conducted using study enrollment data from Project YES! a randomized controlled trial that tested a clinic-based peer mentoring program for HIV-positive adolescents and young adults (AYA) in four clinics in Ndola, Zambia. Once consented and enrolled into the study, Interviews and blood draws for viral load and HIVDR were done after which study participants were randomized to the intervention or delayed intervention arms.

Rationale: Participants were enrolled in and randomized within a clinical trial at the time of sampling.

Answer: Yes
"""

"""
Question: 2703 

Evidence: From December 2017 through May 2018, a total of 276 youth age 15 and 24 years from four clinics were recruited into the parent Project YES! study. We thus analyzed baseline study enrollment data collected through a randomized controlled trial entitled “Project YES! Youth Engaging for Success”.

Rationale: All individuals included in this analysis were recruited into the parent randomized controlled trial.

Answer: Yes
"""

"""
Question: 3101 

Evidence: Out of these 99 participants, HIVDR amplification was successful in 77.8% (n = 77). 

Rationale: The number of individuals with successful amplification corresponds to those who had samples sequenced for HIVDR.

Answer: 77
"""

"""
Question: 3102 

Evidence: Out of these 99 participants, HIVDR amplification was successful in 77.8% (n = 77). A number of specimens with borderline viral loads failed to amplify.

Rationale: Not all eligible individuals had successful sequencing, as some samples failed to amplify.

Answer: No
"""

"""
Question: 4101 

Evidence: Participants were 15 to 24 years old, who knew their HIV status, and had been on ART for at least 6 months. 

Rationale: All participants were ART-experienced; therefore, no ART-naive sequences were reported.

Answer: No
"""

"""
Question: 4102 

Evidence: Participants were 15 to 24 years old, who knew their HIV status, and had been on ART for at least 6 months. Of the 77 youth with HIVDR results, 64 were on first line and 13 were on second line ART (Table 2).

Rationale: All sequenced individuals had prior ARV exposure (first- or second-line).

Answer: Yes
"""

"""
Question: 4103 

Evidence: Participants were 15 to 24 years old, who knew their HIV status, and had been on ART for at least 6 months. Of the 77 youth with HIVDR results, 64 were on first line and 13 were on second line ART (Table 2).

Rationale: The study included only ART-experienced individuals; no ART-naive individuals were sequenced.

Answer: No
"""

"""
Question: 4104 

Evidence: Participants were 15 to 24 years old, who knew their HIV status, and had been on ART for at least 6 months. 

Rationale: Since no ART-naive individuals were included, the count of samples from ART-naive individuals is zero.

Answer: 0
"""

"""
Question: 4105 

Evidence: There had been several ART policy changes that affected ART regimens before the study. Unfortunately, there has been inadequate documentation of reasons for drug changes in most study participants medical charts.

Rationale: The paper explicitly notes inadequate documentation, indicating incomplete ART histories.

Answer: No
"""

"""
Question: 4201 

Evidence: As our study sampled ART treatment experienced AYA, we do not know the prevalence of primary transmitted resistance. 

Rationale: The authors state they did not assess primary (transmitted) resistance.

Answer: No
"""

"""
Question: 4202 

Evidence: As our study sampled ART treatment experienced AYA, we do not know the prevalence of primary transmitted resistance. 

Rationale: Because the study did not include ART-naive individuals, pretreatment drug resistance prevalence is not reported.

Answer: No
"""

"""
Question: 4301 

Evidence: The recommended first-line ART regimens in Zambia at the time of this study comprised of two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) along with a non-nucleoside reverse transcriptase inhibitor (NNRTI). The second line regimens comprised of two NRTIs (TDF or ABC or ZDV plus 3TC or FTC) sequentially selected based on which NRTIs/NtRTIs were used in first line and a boosted protease inhibitor (PI), lopinavir-ritonavir (LPV-r) or atazanavir-ritonavir (ATV-r).

Rationale: These sentences list the ART drug classes administered to participants.

Answer: NRTIs/NtRTIs, NNRTIs, and protease inhibitors
"""

"""
Question: 4302 

Evidence: Finally, raltegravir was the only integrase inhibitor available for use as a third line ART. Dolutagravir had not been introduced to the public health sector until late in the intervention phase of this study and the HIVDR testing did not test for integrase inhibitor gene regions.

Rationale: Although INSTIs were mentioned as available in the health system, the study does not report participants receiving them nor sequencing of integrase.

Answer: No
"""

"""
Question: 4303 

Evidence: The second line regimens comprised of two NRTIs (TDF or ABC or ZDV plus 3TC or FTC) sequentially selected based on which NRTIs/NtRTIs were used in first line and a boosted protease inhibitor (PI), lopinavir-ritonavir (LPV-r) or atazanavir-ritonavir (ATV-r). Table 1 lists second line regimens including Zidovudine/Lamivudine/Lopinavir/ritonavir and other second line regimens with atazanavir boosted by ritonavir.

Rationale: The study documents participants on PI-containing second-line regimens.

Answer: Yes
"""

"""
Question: 4304 

Evidence: Of the 77 youth with HIVDR results, 64 were on first line and 13 were on second line ART (Table 2). Table 1 shows multiple first-line and second-line regimen combinations, including alternate regimens.

Rationale: Participants received varied ART regimens; they did not all receive the same regimen.

Answer: No
"""

"""
Question: 4305 

Evidence: Dolutagravir had not been introduced to the public health sector until late in the intervention phase of this study and the HIVDR testing did not test for integrase inhibitor gene regions. Finally, raltegravir was the only integrase inhibitor available for use as a third line ART.

Rationale: No participants were reported on INSTIs at baseline, indicating the cohort was INSTI-naive.

Answer: Yes
"""

"""
Question: 4403 

Evidence: There had been several ART policy changes that affected ART regimens before the study. Unfortunately, there has been inadequate documentation of reasons for drug changes in most study participants medical charts.

Rationale: Due to inadequate documentation, the number of individuals who received more than one regimen cannot be determined.

Answer: NA
"""

"""
Question: 4404 

Evidence: There had been several ART policy changes that affected ART regimens before the study. Unfortunately, there has been inadequate documentation of reasons for drug changes in most study participants medical charts.

Rationale: The paper lacks sufficient data to determine how many received more than two regimens.

Answer: NA
"""

"""
Question: 4405 

Evidence: There had been several ART policy changes that affected ART regimens before the study. Unfortunately, there has been inadequate documentation of reasons for drug changes in most study participants medical charts.

Rationale: Without complete regimen histories, whether all received the same number of regimens cannot be assessed.

Answer: NA
"""

"""
Question: 4406 

Evidence: There had been several ART policy changes that affected ART regimens before the study. Unfortunately, there has been inadequate documentation of reasons for drug changes in most study participants medical charts.

Rationale: The number of distinct regimens per individual is not documented, so it cannot be concluded that all received only one regimen.

Answer: NA
"""

"""
Question: 4501 

Evidence: Dolutagravir had not been introduced to the public health sector until late in the intervention phase of this study and the HIVDR testing did not test for integrase inhibitor gene regions. Table 1 shows first- and second-line regimens without integrase inhibitors at baseline.

Rationale: Since DTG was not yet introduced during enrollment and no INSTI regimens are listed, no participants received dolutegravir.

Answer: 0
"""

"""
Question: 4502 

Evidence: However, in some cases the PI darunavir boosted by ritonavir was available as a third line option. Table 1 lists second line regimens and does not include darunavir-based regimens.

Rationale: The study documents availability of darunavir in the system but does not report any participants receiving it at baseline.

Answer: 0
"""

"""
Question: 5101 

Evidence: HIV Drug Resistance associated Mutations (DRM) were identified in 75.3% (58/77) of all successful sequences. 

Rationale: The paper directly states that 58 out of 77 sequenced individuals had one or more DRMs.

Answer: 58
"""

"""
Question: 5102 

Evidence: Dolutagravir had not been introduced to the public health sector until late in the intervention phase of this study and the HIVDR testing did not test for integrase inhibitor gene regions. 

Rationale: Integrase was not sequenced; hence no INSTI resistance mutations were detected or reported.

Answer: 0
"""

"""
Question: 5103 

Evidence: The mutation M184V which confers resistance to NRTI drugs of lamivudine (3TC) and emtricitabine (FTC) was the most common (81%) among NRTI associated mutations followed by K65R (34.5%) which is associated with both tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) resistance. K65KR occurred in 20 (34.5%).

Rationale: K65R confers TDF resistance and was present in 20 individuals.

Answer: 20
"""

"""
Question: 5104 

Evidence: Dolutagravir had not been introduced to the public health sector until late in the intervention phase of this study and the HIVDR testing did not test for integrase inhibitor gene regions. 

Rationale: Because integrase was not sequenced and no INSTI use was reported, there are no INSTI-resistance mutations to report.

Answer: NA
"""

"""
Question: 6101 

Evidence: Only viral load results with viral loads of ≥1000 copies/mL were further analyzed for HIVDR using the Stanford University HIV drug resistance mutations database. The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: The study used genotypic resistance interpretation; no phenotypic susceptibility testing method was used.

Answer: NA
"""

"""
Question: 6102 

Evidence: The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/. Drug mutations were categorized based on the WHO2017 drug mutation list and the Stanford HIV drug resistance database (Table 3).

Rationale: There is no reporting of IC50/IC90 values, indicating no novel phenotypic susceptibility metrics.

Answer: No
"""

"""
Question: 6103 

Evidence: Drug mutations were categorized based on the WHO2017 drug mutation list and the Stanford HIV drug resistance database (Table 3). Overall, the 10 most common mutations were M184V ... and E138AGQ (29.3%).

Rationale: The paper reports genotypic mutation frequencies only; no IC50 fold-change phenotypic data are provided.

Answer: No
"""

"""
Question: 6104 

Evidence: Only viral load results with viral loads of ≥1000 copies/mL were further analyzed for HIVDR using the Stanford University HIV drug resistance mutations database. 

Rationale: No phenotypic assay was used; resistance was inferred genotypically.

Answer: NA
"""

"""
Question: 6105 

Evidence: Drug mutations were categorized based on the WHO2017 drug mutation list and the Stanford HIV drug resistance database (Table 3). The most common resistance was to the NRTI group of drugs accounting for 81% (47/58) followed by NNRTI 65% (38/58).

Rationale: The study reports only genotypic resistance data and frequencies; replication capacity was not measured or reported.

Answer: No
"""

"""
Question: 6106 

Evidence: Only viral load results with viral loads of ≥1000 copies/mL were further analyzed for HIVDR using the Stanford University HIV drug resistance mutations database. The outcomes of the HIV resistance tests were reported using the Stanford HIV drug resistance database at http://hivdb.stanford.edu/.

Rationale: No phenotypic susceptibility testing was performed; therefore, no drugs were tested phenotypically.

Answer: NA
"""

"""
Question: 7101 

Evidence: Participants with viral failure (VL >=1,000 copies/mL) underwent HIVDR testing which included analysis of mutations in the protease and reverse transcriptase genes. Genotyping encompassed protease and codons 1--230 of reverse-transcriptase genes.

Rationale: The study analyzed patient-derived viral sequences; it did not create site-directed mutants.

Answer: No
"""

"""
Question: 7102 

Evidence: A cross-sectional analysis of study enrollment data from the Project YES! Youth Engaging for Success randomized controlled trial was conducted. Blood samples with a viral load of >1000 copies/mL (virologic treatment failure) were further subjected to an HIV drug resistance test.

Rationale: The study did not perform in vitro passage; it analyzed clinical samples.

Answer: No
"""